Total results651
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| MTU1 | O75648 | Mitochondrial tRNA-specific 2-thiouridylase 1 (EC 2.8.1.14) (MTO2 homolog) | Disease related genesEnzymesHuman disease related genes | Intellectual disability | Other mediation | 2 | 0.28 | |||
| SLIK6 | Q9H5Y7 | SLIT and NTRK-like protein 6 | Disease related genesHuman disease related genesPredicted membrane proteins | 1 | DeafnessBladder cancerUreteral cancer | Clinical-translation mediation | 2 | 0.28 | ||
| SMOC1 | Q9H4F8 | SPARC-related modular calcium-binding protein 1 (Secreted modular calcium-binding protein 1) (SMOC-1) | Disease related genesHuman disease related genesPredicted secreted proteins | Microphthalmia | Other mediation | 2 | 0.28 | |||
| SSR3 | P32745 | Somatostatin receptor type 3 (SS-3-R) (SS3-R) (SS3R) (SST3) (SSR-28) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Alzheimer diseaseCushing syndromeStomach cancer | Clinical-translation mediationReceptor-signaling mediation | 2 | 0.28 | ||
| T106B | Q9NUM4 | Transmembrane protein 106B | Disease related genesHuman disease related genesPotential drug targets | 1 | Amyotrophic lateral sclerosisLeukodystrophy | Fusion and delivery mediation | 2 | 0.28 | ||
| TLR4 | O00206 | Toll-like receptor 4 (hToll) (CD antigen CD284) | CD markersFDA approved drug targetsHuman disease related genes | 1 | Age-related macular degenerationAllergic/hypersensitivity disorderDiabetes mellitus | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.28 | ||
| TM63C | Q9P1W3 | Osmosensitive cation channel TMEM63C (Calcium permeable stress-gated cation channel 1) (Transmembrane protein 63C) (hTMEM63C) | Disease related genesHuman disease related genesPotential drug targets | 11 | Hereditary spastic paraplegia | Other mediation | 2 | 0.28 | ||
| TMPS2 | O15393 | Transmembrane protease serine 2 (EC 3.4.21.122) (Serine protease 10) [Cleaved into: Transmembrane protease serine 2 non-catalytic chain; Transmembrane protease serine 2 catalytic chain] | Cancer-related genesEnzymesPredicted intracellular proteins | 1 | COVID-19Middle East Respiratory SyndromeSevere acute respiratory syndrome | Clinical-translation mediationMetabolism mediation | 2 | 0.28 | ||
| TNR25 | Q93038 | Tumor necrosis factor receptor superfamily member 25 (Apo-3) (Apoptosis-inducing receptor AIR) (Apoptosis-mediating receptor DR3) (Apoptosis-mediating receptor TRAMP) (Death receptor 3) (Lymphocyte-associated receptor of death) (LARD) (Protein WSL) (Protein WSL-1) | 1 | Solid tumour/cancer | Clinical-translation mediationImmune mediation | 2 | 0.28 | |||
| TNR8 | P28908 | Tumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen) (Lymphocyte activation antigen CD30) (CD antigen CD30) | Cancer-related genesCD markersFDA approved drug targets | 1 | B-cell lymphomaDiabetes mellitusFollicular lymphoma | Clinical-translation mediationImmune mediation | 2 | 0.28 |